Abstract: Monoclonal antibodies directed against coagulation factors and their use in inhibiting thrombosis are disclosed.

Abstract: The invention provides PcrA Helicase polypeptides and polynucleotides encodi PcrA Helicase polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing PcrA Helicase polypeptides to screen for antibacterial compounds.

Abstract: Mouse CC-CKR5 polypeptides and DNA (RNA) encoding such mouse CC-CKR5 and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such mouse CC-CKR5 in the development of gene knockout mice for use as a model for human immunodeficiency virus.

Abstract: A method for normalising abnormally elevated ACTH release in mammals, such as humans, which method comprises the administration of an effective, non-toxic amount of a compound which regulates the biological activity of the arginine vasopressin V1b receptor (the AVP V1b receptor); a compound and composition for use in such method.

Abstract: A method of treating ADHD comprising administering a 5-HT6 receptor antagonist according to formula (A) hereinbelow: wherein: P is phenyl, naphthyl, a bicyclic heterocyclic ring or is a 5 to 7-membered heterocyclic ring each containing 1 to 4 heteroatoms selected from oxygen, nitrogen or sulphur; A is a single bond, a C1-6alkylene or a C1-6alkenylene group; R1 is halogen, C1-6alkyl optionally substituted by one or more halogen atoms, C3-6cycloalkyl, C1-6alkoxy, OCF3, hydroxy, hydroxyC1-6alkyl, hydroxyC1-6alkoxy, C1-6alkoxyC1-6alkoxy, C1-6alkanoyl, nitro, amino, C1-6alkylamino or diC1-6alkylamino, cyano or R1 is phenyl, naphthyl, a bicyclic heterocyclic ring or is a 5 to 7-membered heterocyclic ring each containing 1 to 4 heteroatoms selected from oxygen, nitrogen or sulphur; n is 0, 1, 2, 3, 4, 5 or 6, R2 is hydrogen, C1-6 alkyl or aryl C1-6 alkyl; R3 is a group R5 or together with R5 forms a group (CH2)2O or (CH2)3O or R3 is linked to R2 to form a group (CH2)2 or (CH2)3; R4 is &mdash

Abstract: A mixture of beads of uniform size from is deposited in an array by establishing discrete attachment areas each consisting either of a droplet of adhesive or a small area of a continuous adhesive layer exposed through an aperture in a mask. Beads which are trapped by the attachment areas are released either by a solvent on a vacuum manifold, or by evaporation of the adhesive, preferably by means of a vacuum centrifuge. The beads are released into capillaries, in which cleavage of attached compounds, or synthesis of new compounds, can be carried out. Also invented is the apparatus used in carrying out the invention.

Abstract: p38beta2 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed.

Abstract: Tie2 receptor antagonist antibodies, their use in inhibiting angiogenesis and other uses are disclosed.

Abstract: This invention relates to a process for making certain phenyl urea compounds by using a Lewis acid to effect the ring opening of a benzoxazolinone by an amine.

Abstract: The invention provides prfC polypeptides and DNA (RNA) encoding prfC polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing prfC polypeptides to screen for antibacterial compounds.

Abstract: The enzyme Lp-PLA2 in purified form, an isolated nucleic acid molecule incoding Lp-PLA2, the use of an inhibitor of the enzyme Lp-PLA2 in therapy and a method of screening compounds to identify those compounds which inhibit the enzyme.

Abstract: The invention relates to compounds of formula (I) or a salt thereof wherein X is CH or N; R1 is hydrogen or C1-6 alkyl; R2 and R3 groups are independently C1-6 alkyl, or trifluoromethyl, having pharmacological activity, processes for their preparation, compositions containing them and to their use in the treatment of CNS disorders such as anxiety.

Abstract: hKv4.3 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing hKv4.3 polypeptides and polynucleotides in the design of protocols for the treatment of cardiac arrhythmias and Alzheimer's disease, among others, and diagnostic assays for such conditions.

Abstract: HC/BTLP polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing hC/BTLP polypeptides and polynucleotides in the design of protocols for the treatment of restenosis, atherosclerosis, congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), benign prostatic hypertrophy (BPH), nephritis, fibrosis, glomerulonephritis, gliosis, cirrhosis and anomalies of wound healing, such as keloids among others, and diagnostic assays for such conditions.

Abstract: A process for preparing controlled release solid dosage forms of lithium carbonate by using a dissolution rate stabilizer and a hydrophobic waxy material.

Abstract: The invention provides fabG polypeptides and polynucleotides encoding fabG polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing fabG polypeptides to screen for antibacterial compounds.

Abstract: Heterocycle-condensed morphinoid derivatives of formula (I), or solvates or salts thereof, are potent and selective delta opioid agonists and antagonists and are useful as i.a. analgesics. Pharmaceutical compositions containing such compounds, the use of such compounds as therapeutic agents, a method of treatment comprising the administration of such compounds, and a process for the preparation of such compounds are also described.

Abstract: The H2LAU20 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing H2LAU20 polypeptides and polynucleotides in therapy, and diagnostic assays for such.

Abstract: Tie2 receptor agonist antibodies, their use in enhancing angiogenesis and other uses are disclosed.

Abstract: The present invention relates to 11cby, in particular 11cby polypeptides and 11cby polynucleotides, recombinant materials and methods for their production. In another aspect, the invention relates to methods for using such polypeptides and polynucleotides, including the treatment of bacterial, fungal, protozoan and viral infections, particularly infection caused by HIV-1 or HIV-2; pain; cancers; diabetes; obesity; feeding and drinking abnormalities, such as anorexia and bulimia; asthma; Parkinson's disease; both acute and congestive heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers; allergies; benign prostatic hypertrophy and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia or severe mental retardation, and dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome, hereinafter referred to as “the Diseases”, among others.